Innoviva Inc (INVA.OQ)
3 Aug 2020
Innoviva, Inc., formerly Theravance, Inc., incorporated on November 19, 1996, focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. The Company is also entitled to approximately 15% of any future payments made by GSK under its agreements originally entered into with it, and since assigned to Theravance Respiratory Company, LLC (TRC). RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
2000 Sierra Point Pkwy Ste 500
BRISBANE CA 94005-1830
Company Web Links
Officers & Directors
|45||2018||Independent Chairman of the Board|
|2020||Chief Executive Officer|
|51||2018||Chief Accounting Officer|
- BRIEF-Innoviva Names Pavel Raifeld As Chief Executive Officer
- BRIEF-Innoviva Reports First Quarter 2020 Financial Results
- BRIEF-Innoviva Says Co's 2020 Annual Meeting Of Stockholders Will Be Held In Virtual Meeting Format Only
- BRIEF-GSK Says Filing Accepted By EMA For Trelegy Ellipta Use In Adult Patients With Asthma